We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Umbilical Cord Blood Test Can Detect Early Sepsis in Preterm Infants

By LabMedica International staff writers
Posted on 23 Jun 2025

Diagnosing early onset sepsis (EOS) in preterm infants is particularly difficult due to the lack of specific clinical signs, leading to widespread use of antibiotics while awaiting culture results. More...

Despite negative cultures, approximately 25% of very low birth weight newborns are continued on antibiotics under the presumption of infection. Now, researchers have identified specific proteins in umbilical cord blood that can signal systemic inflammation triggered by infection, offering a new, objective, and noninvasive method to diagnose EOS more accurately and reduce unnecessary antibiotic use.

The solution was developed by scientists from Ann & Robert H. Lurie Children's Hospital of Chicago (Chicago, IL, USA) who published their findings in JCI Insight. Their research focused on preterm newborns and aimed to identify reliable markers of EOS by examining umbilical cord blood collected at birth—a sample that provides a snapshot of the baby’s immune status at delivery. The method hinges on detecting specific proteins in the cord blood that reflect an acute immune response to infection. These biomarkers act as indicators of systemic inflammation, a key feature of EOS. In addition to identifying these proteins, the researchers also developed a machine learning-based diagnostic algorithm that integrates both biomarker data and known clinical risk factors to predict EOS with greater accuracy.

The study revealed that cord blood biomarker results can be processed and made available within 24 hours, allowing physicians to make more informed decisions early on. This timely information helps rule out sepsis confidently and discontinue antibiotics where unnecessary. Given that nearly 78% of very low birth weight infants currently receive antibiotics at birth, the new tool could significantly reduce unwarranted treatment and its associated risks. In practice, the approach offers several advantages. It provides an objective diagnostic aid in a condition often diagnosed based on suspicion alone, reduces prolonged antibiotic exposure, and ultimately lowers the risk of microbiome disruption, immune dysregulation, and other long-term health effects. By facilitating quicker and more precise diagnosis, the cord blood biomarker test and its associated algorithm may improve care standards for some of the most vulnerable newborns.

 


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.